The schizophrenia prodrome: promise for prevention by Cornblatt, Barbara
Converging theoretical, psychopharmacological, and
neurodevelopmental advances have led to increasing
interest in preventive intervention in schizophrenia. In
particular, evidence suggests that early treatment is
associated with a better prognosis. Furthermore, based
on the reported reduction in severe side effects, the
new novel antipsychotics potentially provide the tools
for early intervention. Nevertheless, initiation of inter-
vention during the prodrome has become controver-
sial because of such unresolved issues as: (i) how to
accurately identify susceptible individuals who are in
true need of preventive intervention; (ii) at what devel-
opmental point in the prodrome medication should be
initiated; (iii) how long medication should be contin-
ued; and (iv) what medication is optimal for each phase
of the prodrome. By adopting a naturalistic, prospec-
tive research strategy, the Recognition and Prevention
(RAP) program now underway in New York has been
designed to address these and other important ques-
tions involved in prodromal research and treatment.
nterest in the prodromal stage of schizophre-
nia has escalated dramatically over the past
decade, as evidence has increased suggesting that the
prevention of schizophrenia might be possible with early
pharmaco-therapeutic intervention. The prodrome is
considered to be the stage of schizophrenia that begins
with the first changes in behavior and lasts up until the
onset of psychosis.
1-3 As defined at present, the prodro-
mal period is highly variable and can last from weeks to
years,although typically it persists for at least a year.
1,4
Momentum for the shift in initiating treatment during
the prodrome,rather than after the actual onset of psy-
chosis,has been provided by the convergence of several
developments, including: (i) increasing support for
schizophrenia as a neurodevelopmental disorder; (ii)
emerging evidence that early treatment improves out-
come; and (iii) the introduction of novel antipsychotic
medication,potentially providing the tools for preven-
tive intervention. Yet, despite the growing optimism
about prevention, little is understood about the basic
characteristics of this phase of the illness. For exam-
ple, little, if any, previous research has focused on
whether the prodrome is a single clinical entity or,as in
the case of full-blown schizophrenia, it is likely to be
heterogeneous. In addition, given that adolescents
make up a substantial proportion of the prodromal
population,virtually no information is available about
the developmental course of the prodrome. Of partic-
ular importance, long-term prospective research eval-
uating the predictive accuracy of prodromal risk factors
is only now becoming of widespread interest—sug-
gesting that it may not yet be the time to initiate large-
scale clinical trials concerned with prevention. In this
article, an overview of the currently available data
about the schizophrenia prodrome will be presented,
followed by a discussion of the major questions still to
be answered and a brief description of a relatively new
project ongoing at Hillside Hospital in New York—the
Recognition and Prevention (RAP) program—
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Basic researchdesigned to provide substantial groundwork for future
prevention trials.
Theory and background
Neurodevelopmental model of schizophrenia
A neurodevelopmental view of schizophrenia has provided
the primary conceptual underpinnings of the movement
toward early intervention and prevention. According to
this approach,schizophrenia results from a basic biological
error that occurs very early (probably prenatally), often
involves a genetic component,and leads to a combination
of structural,functional,and/or biochemical abnormalities
in the developing brain.These abnormalities,in turn,result
in a biological susceptibility to illness that may or may not
be triggered by later, poorly understood, stressors. Since
schizophrenia is typically not expressed clinically until late
adolescence–early adulthood,a considerable developmen-
tal time period is thus available during which preventive
treatment can be initiated.
One key to intervention is the ability to accurately iden-
tify who is susceptible to later illness and should thus
receive early treatment. This requires the identification
of accurate risk factors or “predictors” that are not yet
available on an individual level.However,rapid progress
is being made in establishing categories of risk factors.
Traditional genetic high-risk research has indicated that,
although clinically dormant,the biological susceptibility to
schizophrenia is expressed in subtle neurocognitive
deficits that can be detected throughout childhood and
adolescence (see reference 5 for a more detailed discus-
sion).In addition,it is now thought that somewhat later in
the illness process,but still prior to the onset of psychosis,
subclinical behavioral disturbances can also be identified
that may predict later schizophrenia.
6 Thus, from a neu-
rodevelopmental perspective,the unfolding of the clinical
illness is a long-term process,with the identification of at
least two classes of predictors (ie,neurocognitive and pro-
dromal) possible in the near future, suggesting that pre-
ventive intervention may indeed be attainable.
Benefits of early treatment
From a treatment perspective,recent research has inde-
pendently provided a compelling justification for pre-
illness intervention.A number of studies have now sug-
gested that the earlier medication begins after the onset
of psychosis,the better the outcome.
4,6-11 It therefore fol-
lows that intervention initiated prior to onset will be
better still.
The notion that the longer psychosis remains untreated,
the poorer the prognosis,is typically referred to as the dura-
tion of untreated psychosis (DUP) effect. McGlashan
6,12,13
has argued that the DUP effect, in itself, justifies prodro-
mal intervention in spite of the possibility of false-posi-
tive identifications.However,the importance of the DUP
has been increasingly challenged by several more recent
studies,
14-16 in which no association between the DUP and
outcome is reported. Furthermore, several researchers
have raised questions about the direction of causality,
maintaining that, even if there is a correlation between
the DUP and prognosis, this may simply reflect a third
factor,most likely severity of illness.
17
Introduction of novel antipsychotic medications
Until recently, intervention could not be attempted,
regardless of whether stable risk factors could be iden-
tified.This was because standard neuroleptics,the most
effective pharmacological treatment available, were
associated with quite severe side effects (eg, tardive
dyskinesia and other types of movement disorders).
Given the likelihood of involving a relatively high rate of
false-positive identifications,pre-illness intervention was
not considered either feasible or ethical. However, the
emergence of the new novel antipsychotics has changed
this situation and has provided the tools for preventive
intervention.Given the reduced side effects of the novel
antipsychotics currently available,
18-20 intervening early in
the illness process, before psychosis sets in, has been
increasingly regarded as ethically acceptable.
Characterizing the prodrome
The early studies of the prodromal stage of schizophre-
nia,conducted primarily in Germany,were typically ret-
rospective and involved the recollection of the signs and
symptoms preceding onset by patients in the early stages
of illness and their family members.
21-23 The initial pro-
dromal clinical assessment that emerged,the Bonn Scale
for the Assessment of Basic Symptoms (BSABS),
22,24,25
has had a major influence on the development of several
subsequent measures, including: (i) the Instrument for
the Retrospective Assessment of the Onset of Schizo-
phrenia (IROAS),developed by Hafner and colleagues
26-29;
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(ii) the Multidimensional Assessment of the Psychotic
Prodrome (MAPP) used in the Personal Assessment
and Crisis Evaluation (PACE) clinic assessments
30;and,
in turn, (iii) the Structured Interview for Prodromal
Symptoms (SIPS) and Scale of Prodromal Symptoms
(SOPS) developed by McGlashan and colleagues.
31
With the exception of the BSABS,
25 research concerned
with the prospective validity of prodromal assessments,
especially those developed in the United States,has just
begun.
30-34As a result,prodromal diagnostic criteria are
in the process of evolving. In terms of the definitions
most widely used at present,much of the groundbreak-
ing work has been carried out by McGorry and col-
leagues in Australia.
30,32-34 Based on a series of creative
early studies, they have developed a highly influential
set of criteria for identifying prodromal individuals.
Their system consists of three separate categories of
selection criteria.
35 Category 1 requires at least one of
the following attenuated (ie, subthreshold) positive
symptoms: ideas of reference, odd beliefs, or magical
thinking; perceptual disturbance; odd thinking and
speech;paranoid ideation;and odd behavior or appear-
ance.Category 2 consists of individuals who have expe-
rienced transient psychotic symptoms that have spon-
taneously resolved within 1 week.Category 3 combines
genetic risk (ie,being the first-degree relative of an indi-
vidual with a diagnosis of schizophrenia) with state
change in functioning (must have undergone a sub-
stantial decline in the previous year).These categories
have also been integrated into the SIPS and SOPS
developed by McGlashan and colleagues.
31
Unanswered questions
Heterogeneity and false-positive identifications
The prodrome is typically considered to be a unitary clin-
ical entity.This appears to be overly simplistic from a num-
ber of perspectives.First,in the McGorry/McGlashan cri-
teria described above,there is no evidence to indicate that
the three categories presented involve a common etiolo-
gy.In fact,there is no reason to think that the prodrome is
etiologically less heterogeneous than the full illness. Sec-
ond,it should be noted that most of the criteria discussed
above are derived from positive symptoms; the focus on
attenuated positive symptoms may be both overly restric-
tive and lead to an unacceptably high false-positive rate.
Although deriving prodromal criteria from positive symp-
toms provides considerable face-validity, the accuracy
with which these indicators actually predict schizophrenia,
or even psychosis,is unestablished.For example,McGorry
et al
3 reported that approximately half of the 657 high-
school students completing a self-report questionnaire
met criteria for the prodromal phase of schizophrenia as
defined by Diagnostic and Statistical Manual of Mental
Disorders,Revised Third Edition (DSM-III-R) attenuated
positive symptoms. Similarly, positive schizophrenia-like
personality features have also been found in clinically
normal individuals as well as in patients with a variety of
nonpsychotic disorders, such as adults with dyslexia.
36
Such findings raise questions about the rate of false pos-
itives resulting from a reliance on positive symptoms.The
issue of false positives is particularly important for pre-
vention trials involving pharmacotherapy. Although the
side-effect profile of the new novel antipsychotics
appears, at this time, to be less severe than that associ-
ated with traditional neuroleptics,there are nevertheless
side effects,such as substantial weight gain,to consider.In
addition, the impact of long-term treatment on adoles-
cent neurological development has yet to be determined.
Negative symptoms
There is considerable evidence to suggest that attenu-
ated negative symptoms, such as deficits in social func-
tioning, are important characteristics of the prodromal
phase of the illness.
25,26,37-39 Several genetics studies have
demonstrated that social deficits and other negative
symptoms are more characteristic of the relatives of
patients with schizophrenia than are positive symp-
toms.
40-42 Furthermore, prospective birth cohort studies
of schizophrenia have consistently detected social
deficits very early in development, prior to the onset
of positive symptoms.
43,44
The omission of attenuated negative symptoms in the
most recent prodromal assessments (eg, SIPS and
SOPS)
31 parallels the reliance on positive symptoms for
a diagnosis of Axis I schizophrenia. However, in so
doing, major early features of the prodrome may be
missed. It may be at the stage where nonspecific, atten-
uated negative symptoms begin to emerge that inter-
ventions not involving antipsychotic medications are
most effective. Moreover, it is possible that a combina-
tion of attenuated negative/disorganized and attenuated
positive symptoms will prove to be the most accurate
way of defining the prodrome.
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Medication issues: what kind to use, when,
and for how long?
In keeping with the view of the prodrome as a single
clinical entity, it has been assumed by most clinical
researchers that antipsychotic medication should be
the starting point for intervention trials. On the sur-
face,this appears to be a logical extension of treatment
for the full disorder. However, by definition, individu-
als considered to be prodromal do not display florid
psychotic symptoms, the symptoms most improved by
antipsychotic medication. As a result, other pharma-
cological interventions must be considered. For exam-
ple, it is possible that medications decreasing stress
may reduce the risk of clinical deterioration in suscep-
tible individuals, at least in the early stages of the pro-
drome.
Moreover,in contrast with the absence of psychotic fea-
tures, neurocognitive deficits have been consistently
reported to characterize both premorbid
5,45-48 and pro-
dromal
49,50 stages of schizophrenia. These data suggest
that neurocognitive deficits should therefore be a pri-
mary medication target. However, a number of
researchers have reported that standard neuroleptics
have little, if any, positive effect on neurocognition in
individuals with schizophrenia.
51,52 There is some pre-
liminary evidence to suggest that novel antipsychotics
are more effective in treating specific cognitive
deficits.
53-56 However,this evidence is still relatively pre-
liminary, and it does not appear that any one agent
affects cognition in general.As a result, optimal treat-
ment may involve an as-yet unidentified pharmacolog-
ical agent that directly improves cognition across a wide
range of functions.
Finally,a number of additional,related questions remain
to be addressed before treatment with antipsychotics
(or other pharmacological agents) can be generally sup-
ported.For example,no information is available to guide
length of treatment in prodromal individuals. Even for
individuals definitely diagnosed to have schizophrenia,it
is unclear as to how long treatment with antipsychotic
medication should continue.
11 This issue is particularly
important when considering prolonged use of antipsy-
chotics, since many patients may still be in their teens
and not yet have completed their neurological develop-
ment.
An additional interrelated concern involves the lack of
solid information describing the developmental course
of the prodromal phase.The prodromal stage of schizo-
phrenia is a complex clinical construct in its own right.
The extent to which there are stages of the prodrome
that are common to most individuals (for example, as
hypothesized by Cornblatt and colleagues (private com-
munication),attenuated negative symptoms followed by
attenuated positive symptoms) is unknown.Such infor-
mation would contribute to an understanding of when
treatment should be initiated and what type of treat-
ment is most appropriate for each prodromal phase. In
our research program at Hillside Hospital,we have pro-
posed that a naturalistic prospective research strategy
can help to clarify the major developmental and clinical
characteristics of the prodrome and answer many of the
unresolved issues discussed above.
The Hillside Recognition 
and Prevention (RAP) program
The Recognition and Prevention (RAP) program of
Hillside Hospital of the North Shore–Long Island Jew-
ish Health System in New York is designed to prospec-
tively characterize the schizophrenia prodrome and
evaluate a range of early interventions, including vari-
ous psychosocial and psychopharmacological therapies.
The program consists of the RAP clinic,which provides
treatment for prodromal adolescents, and a number of
related research projects. Since prevention involves
both the accurate identification of vulnerable individu-
als and the administration of effective treatments,both
are major foci of the program. In terms of selection, a
major goal of the RAP program is to establish a pre-
dictor profile that will combine the most accurate neu-
rocognitive and prodromal (behavioral) risk factors.
With respect to treatment, our strategy is to first con-
duct a naturalistic study of treatment effects.To do this,
we currently treat “prodromal”symptoms as they would
be treated in the real world; in other words, treatment
targets specific symptoms rather than attempting pre-
vention. As a result, RAP clinic interventions do not
necessarily involve antipsychotic medication. In fact,
preliminary data collected from a recently completed 3-
year pilot study involving 50 prodromal adolescents
have suggested that antidepressants are as effective as
antipsychotics in improving overall level of functioning
in individuals free of overt psychotic symptoms.
By following a naturalistic prospective study design
and treatment strategy for a minimum of 5 years, we97
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hope to pinpoint the therapies most appropriate for
specific symptoms and developmental stages of the
prodrome and to address many of the other questions
raised in the discussion above.Our long-term goals are
to establish a highly accurate system of early detection
and to develop clinical trials on the basis of our natu-
ralistic findings, and thus move increasingly closer to
prevention. ❏
El pródromo esquizofrénico: una promesa
para la prevención
Una convergencia de los progresos teóricos, psi-
cofarmacológicos y del neurodesarrollo ha con-
ducido a incrementar el interés en una interven-
ción preventiva en la esquizofrenia. En particular,
la evidencia sugiere que el tratamiento precoz
está asociado con un mejor pronóstico. Además,
de acuerdo con las publicaciones sobre la reduc-
ción de los efectos secundarios severos, los antip-
sicóticos más modernos potencialmente proveen
las herramientas para una intervención precoz.
Sin embargo, el comienzo de la intervención
durante el pródromo ha llegado a ser controver-
tida debido a algunos aspectos no resueltos
como: 1) ¿cómo identificar con precisión a aque-
llos individuos susceptibles que tienen una verda-
dera necesidad de una intervención preventiva?,
2) ¿en qué momento del desarrollo del pródromo
se debe iniciar la medicación?, 3) ¿por cuánto
tiempo debe mantenerse la medicación? y 4)
¿qué medicación es óptima para cada fase del
pródromo? Mediante la adopción de una estrate-
gia naturalística y de una investigación prospecti-
va, el Programa de Reconocimiento y Prevención
(PRP) que actualmente se lleva a cabo en Nueva
York, ha sido diseñado para aclarar éstas y otras
preguntas que surgen en la investigación y el tra-
tamiento del pródromo.
Le prodrome schizophrénique : une promes-
se pour la prévention
Les avancées convergentes tant sur le plan théo-
rique, psychopharmacologique que du neurodé-
veloppement de la schizophrénie se sont traduites
par un intérêt croissant pour la prévention de
cette affection. En particulier, il semble acquis que
le traitement précoce assure un meilleur pronos-
tic. De plus, les nouveaux antipsychotiques de
deuxième génération, du fait qu'ils sont caractéri-
sés par une diminution avérée d’effets secondaires
graves, pourraient constituer l’outil de cette pré-
vention précoce. Néanmoins, une intervention
pendant la phase prodromique demeure contro-
versée en raison des questions suivantes toujours
en suspens : (1) comment identifier avec exactitu-
de les patients nécessitant effectivement une pré-
vention ? (2) à quel stade de la phase prodro-
mique le traitement doit-il être débuté ? (3)
combien de temps le traitement doit-il être pour-
suivi ? et (4) quel est le traitement optimal pour
chaque stade de la phase prodromique ? Adop-
tant une stratégie de recherche prospective et
naturaliste, le programme " Recognition and Pre-
vention " (Reconnaissance et Prévention) actuel-
lement en cours à New York a été élaboré pour
répondre à ces questions et à d’autres aussi impor-
tantes concernant la recherche et le traitement
relatifs à la phase prodromique.
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